UBS Group Cuts Danaher (NYSE:DHR) Price Target to $305.00

Danaher (NYSE:DHR) had its target price cut by analysts at UBS Group from $309.00 to $305.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the conglomerate’s stock. UBS Group’s price objective would suggest a potential upside of 19.66% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. Robert W. Baird dropped their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday. KeyCorp upped their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday. Stephens assumed coverage on shares of Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Danaher in a report on Friday, September 6th. Finally, Wells Fargo & Company began coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective on the stock. Seven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $286.39.

Danaher Stock Performance

Shares of Danaher stock traded down $6.39 on Wednesday, reaching $254.89. The stock had a trading volume of 1,656,408 shares, compared to its average volume of 2,719,696. The stock has a market cap of $188.79 billion, a P/E ratio of 43.20, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The business’s 50-day moving average price is $270.67 and its two-hundred day moving average price is $260.46. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the company earned $2.02 EPS. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. On average, sell-side analysts forecast that Danaher will post 7.59 EPS for the current year.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 over the last ninety days. 11.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tsfg LLC grew its position in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher during the second quarter worth about $25,000. nVerses Capital LLC bought a new stake in Danaher in the second quarter valued at approximately $25,000. Redmont Wealth Advisors LLC bought a new stake in Danaher in the first quarter valued at approximately $30,000. Finally, MFA Wealth Advisors LLC bought a new stake in Danaher in the second quarter valued at approximately $51,000. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.